Daunorubicin
Brand: Cerubidine (global) / Daunoblastin (IN/BD)
Anticancer
Anthracycline (topoisomerase II inhibitor)
Pharmacokinetics
| Half-life | 19 hours |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Similar cardiotoxic profile to doxorubicin; lifetime cumulative dose applies. |
⚠️ Safety & Warnings
Severity: Life-threatening
Adverse Effects:
Myelosuppression, cardiomyopathy, mucositis, red/orange urine
Contraindications:
Severe cardiac dysfunction
Precautions:
Monitor cardiac function and CBC; high cardiotoxicity risk